Literature DB >> 29074548

Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease.

Jules Derks1, Robert Jan van Suylen2, Erik Thunnissen3, Michael den Bakker4,5, Harry Groen6, Egbert Smit7,8, Ronald Damhuis9, Esther van den Broek10, Ernst-Jan Speel11, Anne-Marie C Dingemans12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29074548     DOI： 10.1183/13993003.01658-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

1.  Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.

Authors:  Shuwen Zhang; Jingjing Chen; Rui Zhang; Liqin Xu; Yan Wang; Zaixin Yuan; Xiaohui Hou; Jian Feng
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-06       Impact factor: 4.553

Review 2.  Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.

Authors:  Colin R Lindsay; Emily C Shaw; David A Moore; Doris Rassl; Mariam Jamal-Hanjani; Nicola Steele; Salma Naheed; Craig Dick; Fiona Taylor; Helen Adderley; Fiona Black; Yvonne Summers; Matt Evans; Alexandra Rice; Aurelie Fabre; William A Wallace; Siobhan Nicholson; Alex Haragan; Phillipe Taniere; Andrew G Nicholson; Gavin Laing; Judith Cave; Martin D Forster; Fiona Blackhall; John Gosney; Sanjay Popat; Keith M Kerr
Journal:  Br J Cancer       Date:  2021-09-06       Impact factor: 9.075
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.